Clinical Research Directory

Inclusion Criteria (Justification in parenthesis): * Age ≥18 years (RC and EC are primarily adult-onset cancers, and adult inclusion aligns with ethical biospecimen collection and consent processes.) * Histologically confirmed diagnosis of rectal or esophageal cancer (Confirms clinical relevance and eligibility for standard treatment pathways.) * Treatment plan includes surgical resection with curative intent (Ensures applicability to MRD and outcome prediction tasks.) * Undergoing standard-of-care neo-adjuvant or perioperative therapy (Ensures data consistency and relevance to response modelling.) * Ability and willingness to provide informed consent for biospecimen and clinical data use (Meets ethical requirements for participation.) * Availability for longitudinal blood sampling at T0 (baseline), T1 (3 months post-treatment), and T2 (6 months post-treatment) (Critical for temporal biomarker analysis.) * Optional Inclusion: Access to tumor tissue (archival or fresh) for multi-omic profiling (Supports deep integrative biomarker discovery.) Exclusion Criteria: * Diagnosis of non-resectable or metastatic disease at enrollment (Excludes non-curative settings where the longitudinal biomarker protocol may not be feasible.) * Emergency surgeries or treatment plans that deviate from standard protocols (To maintain data comparability.) * Inability or refusal to provide informed consent (Essential for ethical compliance.) * Failure to complete biospecimen donation or key follow-up timepoints (Maintains data integrity and model reliability.)